Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of results from a Phase Ib/IIa study for GZR18, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, at the American Diabetes Association’s (ADA’s) 84th Scientific Sessions. The study evaluated GZR18’s efficacy in weight reduction for obese/overweight Chinese individuals, along with two pre-clinical studies for novel insulins.
The study results indicated superior weight reduction efficacy for GZR18 compared to placebo in Chinese obese subjects. After 35 weeks of treatment, the mean weight change from baseline in the GZR18 QW group was -16.5 kg, with a placebo-adjusted mean percent weight change from baseline of -18.6%. This outperformed the weight reduction abilities of similar products like semaglutide and tirzepatide in similar study durations. Additionally, the GZR18 Q2W group experienced a mean weight change from baseline of -11.3 kg, with a placebo-adjusted mean percent weight change from baseline of -13.5%.
Furthermore, Gan & Lee presented preclinical trial results for GZR4, a once-weekly insulin analog, and GZR101, a premixed dual insulin analog, at the ADA’s 84th Scientific Sessions. GZR4 is a novel ultra-long-acting basal insulin analog designed for once-weekly administration, showing a significantly higher affinity for human serum albumin (HSA) and a lower affinity for the insulin receptor compared to insulin Icodec, another once-weekly insulin analog. GZR101 injection is a premixed insulin analog combining ultra-long-acting basal insulin GZR33 injection and rapid-acting insulin aspart (Rapilin). Unlike traditional premixed insulin analogs, GZR101’s basal insulin component (GZR33) has a glucose-lowering effect duration of up to 72 hours, with no significant peak within 24 hours after reaching a steady state with multiple injections. This combination aims to achieve smooth control of fasting and postprandial blood glucose levels throughout the day.- Flcube.com
